$XTALPI(02228.HK) Stay patient. The big contract is coming soon. PharmaTech's business model is unprecedented in this industry. It is essentially a platform, an enabler, rather than directly engaging in pipelines. From a certain perspective, market understanding and pricing take time. The previous $100 million contract is currently under technical due diligence, and I believe the execution of this contract will be a significant turning point. Judging from PharmaTech's recent series of acquisitions/investments in the capital market, it seems aware of the skepticism and concerns about such a platform-based business model. Therefore, it is also extending to more downstream pipelines/manufacturing through M&A/investments. But first and foremost, it is a platform, so it cannot directly compete with pipeline clients, which requires an optimization of the business model. This takes time. If you're worried, reduce your position. All problems stem from positions. All opportunities also come from positions. My personal view is that to make big money, you need to participate with heavy positions, but heavy positions require withstanding the associated risks and volatility. There are no linearly growing asset prices in the world. Behind this lies portfolio management, risk tolerance, asset cognition, and a bit of luck, such as the entry point, etc.